Granted I do not have laser insight into the full

Granted I do not have laser insight into the full spectrum of ownership of the current float but I do have a very strong impression that it resides in the hands of longs pretty well acquainted with what Leronlimab can do. Weak hands stood aside long ago and shares have moved inexorably into the hands of conviction that will not sell at current levels. The MM can sell naked shares temporarily but even those in theory have to be covered in a timely fashion. It is a real stretch to suggest some BP will come into the market and acquire a majority…they could but not at current prices. The volume needed to acquire that majority voting share would leave a massive footprint on the market and the only way to be successful would be on a significant bid from current price to tease/wrest it away from current owners. Flippers looking to make a deal will come to regret it. Again, the big money is in the big swing…I am under no illusion that will be 3 fingers but you may need to clear the old high of $10 for the votes to come in. If Cytodyn pivots to partnership and gets additional positive trial data, even if just the HIV inflammation study which tips the scale at $2-3 million and something less than 1year to full enrollment (likely very rapid), data lock, read-out and results, that alone might take out the old high due to the spotlight on other indications owing to appreciation of Leronlimab for its immune modulator mechanism.

That said I suspect Jay et al are multi-threading other options in parallel, perhaps a PASC grant from the NIH. What needs to happen in background is not quick, requires paperwork, negotiation etc.

It is hard to wait but when news comes you might find yourself surprised along with the market. Like Black Ops said, don’t lose your position. If you are feeling blue now imagine how you will feel if you lost your position and then witnessed what has high odds of coming to pass.